Instrumentation Laboratory Introduces Automated HemosIL VWF Ristocetin Cofactor Activity Assay in Europe and International Regions
BEDFORD, Mass., Nov. 29, 2011 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of the new HemosIL von Willebrand Factor Ristocetin Cofactor Activity (VWF: RCo) assay as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices. It will be commercialized in Europe and other international regions. This new, fully automated VWF: RCo assay is for use on the ACL TOP® Family of Hemostasis Testing Systems. Together with other HemosIL reagents (HemosIL VWF Antigen, HemosIL VWF Activity, and HemosIL FVIII), it aids in the diagnosis and monitoring of von Willebrand Disease (VWD).
Based on new proprietary technology, the assay represents an innovative approach to VWD testing. Demonstrating excellent agreement with existing ristocetin-platelet-based tests, the HemosIL VWF: RCo assay eliminates platelet-associated variability. The result is superior precision. Additionally, variability associated with human interpretation, common with manual testing methods, is eliminated. Moreover, because the assay is automated, liquid and ready-to-use, results are available in minutes and on-demand, 24/7.
"This important new addition to our portfolio of VWF assays will help ensure early diagnosis and proper treatment for patients," said Remo Tazzi, Director, Hemostasis Marketing at IL. "By simplifying and automating a complex procedure, the HemosIL VWF: RCo assay marks a significant improvement in not only the turnaround time for results, but also in accuracy and precision. It is a perfect example of our commitment to providing specialized solutions for disease-state management."
About von Willebrand Disease
VWD is the most common inherited blood disorder, occurring in app